<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085445</url>
  </required_header>
  <id_info>
    <org_study_id>S2460</org_study_id>
    <nct_id>NCT04085445</nct_id>
  </id_info>
  <brief_title>An &quot;All-Comers&quot; Study of the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter Used in Real-World Clinical Practice in Chinese Patients</brief_title>
  <official_title>Agent DCB Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compile the real-world clinical outcome data for the AgentTM MONORAILTM Paclitaxel-Coated
      PTCA Balloon Catheter (Agent DCB) used in percutaneous coronary intervention (PCI) in Chinese
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Agent DCB Registry study will enroll 500 subjects at up to 10 investigational sites in
      Taiwan, Hong-Kong and Singapore.

      If participants decide to participate in this study, participants will first be asked to sign
      and date this consent form. If participants sign the consent form, participants will go
      through a baseline/ procedure process. Information about participants and participants'
      health will be collected and participants will have a limited physical examination.

      Participants will need to have the laboratory tests (including myocardial enzyme test before
      and post the index procedure, pregnancy test before the index procedure) and other
      assessments to find out if participants meet the requirements to be in the study and to
      ensure it is safe for participants to have the procedure. These tests and assessments are
      part of routine care and may be done even if participants do not join the study. If
      participants have had some of them recently, they may not need to be repeated.

      Participants will be expected to follow the scheduled follow-ups which occur at 30 days, 6
      and 12 months, and then annually through 3 years post the index procedure for all enrolled
      subjects. Angiographic follow-up will perform at 9 months post index procedure for all the
      subjects with small vessel lesions and the first 100 consecutively enrolled subjects with ISR
      lesions. Enrolled subjects with the failure of advancing Agent DCB across target lesion will
      be followed through hospital discharge following the initial attempted index procedure.

      Participants' participation in the study will be completed after approximately 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Number of Participants with 12 months post index procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Major adverse cardiac event (MACE) rate, defined as cardiac death, myocardial infarction (MI, Q-wave and non-Q-wave) and target vessel revascularization (TVR),Target lesion revascularization (TLR) and target lesion failure (TLF) rates</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Chinese Patients Treated With Agent DCB</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter</intervention_name>
    <description>To compile the real-world clinical outcome data for the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter (Agent DCB) used in percutaneous coronary intervention (PCI) in Chinese patients.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All enrolled subjects will be eligible for evaluation. The inclusion and exclusion criteria
        for the Agent DCB Registry study are listed in the following sections.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese subject at least 18 years of age(or meet age requirements per local law).

          -  Subject (or legal guardian) who understands the study requirements and the treatment
             procedures and provides written informed consent before any study-specific tests or
             procedures are performed.

          -  Subject who has ischemic symptoms or evidence of myocardial ischemia and is clinically
             indicated for PCI and will be treated with Agent DCB.

          -  Subject is willing to comply with all protocol-required follow-up evaluation.

          -  In women with childbearing potential a negative pregnancy test is mandatory.

          -  Subject with no known intolerance to paclitaxel and no contraindications to
             antiplatelet regimen.

        Exclusion Criteria:

        - Exclusion criteria are not required in the Agent DCB registry study as it is an &quot;all
        comers&quot; study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joyce Lee</last_name>
    <phone>886-2-26528126</phone>
    <email>Joyce.Lee@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yiu Tung Anthony Wong</last_name>
      <phone>852 2255 2563</phone>
      <email>anthonyytw@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hee Hwa Ho</last_name>
      <phone>6562566011</phone>
      <email>hee_hwa_ho@ttsh.com.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng-Yu Kuo</last_name>
      <phone>886-7-3422121</phone>
      <phone_ext>2011</phone_ext>
      <email>fykuo@vghks.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Sheng Chang</last_name>
      <phone>886-4-22052121</phone>
      <phone_ext>2323</phone_ext>
      <email>chssheng@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsu-Lung Jen</last_name>
      <phone>886-2-28264400</phone>
      <phone_ext>3480</phone_ext>
      <email>ckp807@yahoo.com.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Ting Tsai</last_name>
      <phone>886-2-25433535</phone>
      <phone_ext>3261</phone_ext>
      <email>chengtingtsai@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hsien-Li Kao</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>63671</phone_ext>
      <email>hsienli_kao@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tse-Min Lu</last_name>
      <phone>886-2-28712121</phone>
      <phone_ext>3794</phone_ext>
      <email>tmlu@vghtpe.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Agent DCB</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

